These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29550338)

  • 1. Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence.
    Gavazzoni M; Vizzardi E; Gorga E; Bonadei I; Rossi L; Belotti A; Rossi G; Ribolla R; Metra M; Raddino R
    Eur J Pharmacol; 2018 Jun; 828():80-88. PubMed ID: 29550338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
    Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy.
    Zheng Y; Huang S; Xie B; Zhang N; Liu Z; Tse G; Liu T
    Curr Probl Cardiol; 2023 Mar; 48(3):101536. PubMed ID: 36481392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
    Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ
    J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome and proteasome inhibitors in multiple myeloma.
    Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
    Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.
    Wu P; Oren O; Gertz MA; Yang EH
    Curr Oncol Rep; 2020 Jun; 22(7):66. PubMed ID: 32514632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects.
    Gavazzoni M; Lombardi CM; Vizzardi E; Gorga E; Sciatti E; Rossi L; Belotti A; Rossi G; Metra M; Raddino R
    Eur J Pharmacol; 2018 Nov; 838():85-90. PubMed ID: 30201379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma.
    Cole DC; Frishman WH
    Cardiol Rev; 2018; 26(3):122-129. PubMed ID: 29077585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological Changes within the Rat Lateral Ventricle after the Administration of Proteasome Inhibitors.
    Wójcik S; Spodnik JH; Dziewiątkowski J; Spodnik E; Moryś J
    PLoS One; 2015; 10(10):e0140536. PubMed ID: 26479862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotoxicity induced by antineoplastic proteasome inhibitors.
    Alé A; Bruna J; Navarro X; Udina E
    Neurotoxicology; 2014 Jul; 43():28-35. PubMed ID: 24525285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitor-induced gastrointestinal toxicity.
    Stansborough RL; Gibson RJ
    Curr Opin Support Palliat Care; 2017 Jun; 11(2):133-137. PubMed ID: 28333868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors.
    Cvek B
    Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.
    Tjionas H; Gupta AK
    J Oncol Pharm Pract; 2017 Mar; 23(2):152-156. PubMed ID: 26786028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.
    Acosta-Alvear D; Cho MY; Wild T; Buchholz TJ; Lerner AG; Simakova O; Hahn J; Korde N; Landgren O; Maric I; Choudhary C; Walter P; Weissman JS; Kampmann M
    Elife; 2015 Sep; 4():e08153. PubMed ID: 26327694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
    Lee SJ; Levitsky K; Parlati F; Bennett MK; Arastu-Kapur S; Kellerman L; Woo TF; Wong AF; Papadopoulos KP; Niesvizky R; Badros AZ; Vij R; Jagannath S; Siegel D; Wang M; Ahmann GJ; Kirk CJ
    Br J Haematol; 2016 Jun; 173(6):884-95. PubMed ID: 27071340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect.
    Kaplan GS; Torcun CC; Grune T; Ozer NK; Karademir B
    Free Radic Biol Med; 2017 Feb; 103():1-13. PubMed ID: 27940347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy activation can partially rescue proteasome dysfunction-mediated cardiac toxicity.
    Papanagnou ED; Gumeni S; Sklirou AD; Rafeletou A; Terpos E; Keklikoglou K; Kastritis E; Stamatelopoulos K; Sykiotis GP; Dimopoulos MA; Trougakos IP
    Aging Cell; 2022 Nov; 21(11):e13715. PubMed ID: 36259256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.